While previous research has proven the role of MHC-I molecules, a new study in Cell suggests that MHC-II may also serve as a target in immunotherapy.
A study in JAMA Oncology found that a wide range of fatal toxic events can occur with immune checkpoint inhibitors, and the type of event varies by agent.
New research in Lancet Oncology confirms previous studies in this population on the addition of apalutamide to androgen deprivation therapy.
A study in Cancer found a lower risk of prostate cancer–specific death and improved overall survival when patients were treated with this combination.
By elevating the expression of ANO7, a potential prostate cancer susceptibility gene, it may be possible to predict disease severity and outcome.
Individuals who develop frequent basal cell carcinomas may have an increased prevalence of germline mutations in DNA repair genes and an increased malignancy risk.
Although the study found lurbinectedin isn't promising, the presence of a chromosomal 11q21-23 abnormality may open doors in treating the disease.
A particular gatekeeper—the nuclear pore protein called POM121—traffics molecules that increase tumor aggressiveness in prostate cancer.
Taking corticosteroids at the time of treatment initiation with PD-L1 inhibitors may lead to inferior outcomes in patients with non–small-cell lung cancer.
MRI-guided laser interstitial thermal therapy appears to be safe and effective for glioblastomas and may add an average of 2 months to life expectancy.